Revenue vs Net income
Reported dollars from 10-Q / 10-K filings. Q4 bars are derived (annual less nine months) where the 10-K does not tag Q4 separately.
Margin trend
Gross, operating and net margin. Margins are derived from reported dollars.
Revenue YoY growth
Year-over-year change vs the same quarter (or fiscal year) a year earlier. Shown where the prior-year period is in the 8-quarter snapshot (latest four quarters).
Income statement
From 10-Q / 10-K XBRL. Values in reported dollars; EPS in $/share; share counts in shares.
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B |
| YoY | — | +0.8% | +19.6% | +32.0% | +44.7% |
| Cost of goods sold | $7.3B | $6.6B | $7.1B | $8.4B | $11.1B |
| YoY | — | -9.3% | +6.8% | +18.9% | +31.3% |
| Gross profit | — | — | — | — | — |
| YoY | — | — | — | — | — |
| Research & development | — | — | — | — | — |
| YoY | — | — | — | — | — |
| Selling, general & administrative | $6.4B | $6.4B | $7.4B | $8.6B | $11.1B |
| YoY | — | +0.1% | +15.0% | +16.1% | +29.1% |
| Operating income | — | — | — | — | — |
| YoY | — | — | — | — | — |
| Pretax income | $6.2B | $6.8B | $6.6B | $12.7B | $25.7B |
| YoY | — | +10.6% | -3.7% | +93.5% | +102.9% |
| Income tax | $573.8M | $561.6M | $1.3B | $2.1B | $5.1B |
| YoY | — | -2.1% | +134.0% | +59.1% | +143.6% |
| Net income | $5.6B | $6.2B | $5.2B | $10.6B | $20.6B |
| YoY | — | +11.9% | -16.1% | +102.1% | +94.9% |
| EPS — basic | $6.15 | $6.93 | $5.82 | $11.76 | $23.00 |
| YoY | — | +12.7% | -16.0% | +102.1% | +95.6% |
| EPS — diluted | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 |
| YoY | — | +12.7% | -15.9% | +101.9% | +96.0% |
| Weighted shares — basic | 907.0M | 901.7M | 900.2M | 900.6M | 897.3M |
| Weighted shares — diluted | 911.7M | 904.6M | 903.3M | 904.1M | 899.3M |
Balance sheet
Point-in-time values at each quarter (or fiscal year) end.
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Cash & equivalents | $3.8B | $2.1B | $2.8B | $3.3B | $7.3B |
| YoY | — | -45.9% | +36.4% | +15.9% | +122.4% |
| Marketable securities (current) | — | — | — | — | — |
| YoY | — | — | — | — | — |
| Accounts receivable | $6.7B | $6.9B | $9.1B | $11.0B | $17.8B |
| YoY | — | +3.3% | +31.8% | +21.1% | +61.4% |
| Inventory | $3.9B | $4.3B | $5.8B | $7.6B | $13.7B |
| YoY | — | +10.9% | +33.9% | +31.5% | +81.1% |
| Total current assets | $18.5B | $18.0B | $25.7B | $32.7B | $55.6B |
| YoY | — | -2.3% | +42.7% | +27.3% | +69.9% |
| Total assets | $48.8B | $49.5B | $64.0B | $78.7B | $112.5B |
| YoY | — | +1.4% | +29.3% | +23.0% | +42.9% |
| Total current liabilities | $15.1B | $17.1B | $27.3B | $28.4B | $35.2B |
| YoY | — | +13.9% | +59.3% | +4.0% | +24.1% |
| Total liabilities | — | — | — | — | — |
| YoY | — | — | — | — | — |
| Total equity | $9.0B | $10.6B | $10.8B | $14.3B | $26.5B |
| YoY | — | +18.6% | +1.1% | +32.5% | +85.9% |
| Shares outstanding | — | — | — | — | — |
| YoY | — | — | — | — | — |
Cash flow
Quarterly values derived from year-to-date filings (Q4 from the 10-K). Free cash flow = operating cash flow − capital expenditures.
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Operating cash flow | $7.4B | $7.6B | $4.2B | $8.8B | $16.8B |
| YoY | — | +3.0% | -44.1% | +108.0% | +90.7% |
| Capital expenditures | — | — | — | — | — |
| YoY | — | — | — | — | — |
| Free cash flow | — | — | — | — | — |
| YoY | — | — | — | — | — |
| Dividends paid | $3.1B | $3.5B | $4.1B | $4.7B | $5.4B |
| YoY | — | +14.5% | +15.1% | +15.0% | +15.0% |
| Share repurchases | $1.2B | $1.5B | $750.0M | $2.5B | $4.1B |
| YoY | — | +20.0% | -50.0% | +233.3% | +64.3% |
Margins & ratios
Derived from the reported dollars above — no separate source.
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
| Free cash flow margin | — | — | — | — | — |
| Effective tax rate | 9.3% | 8.3% | 20.0% | 16.5% | 19.8% |
| Current ratio | 1.23x | 1.05x | 0.94x | 1.15x | 1.58x |
| Total liabilities / equity | — | — | — | — | — |
Peer comparison — latest full year
Same sector (Health Care), sorted by revenue. All figures from the same EDGAR XBRL snapshot.
| Ticker | Revenue | Revenue YoY | Gross margin | Operating margin | Net margin | FCF margin |
|---|---|---|---|---|---|---|
| LLY FY25 · this stock | $65.2B | +44.7% | — | — | 31.7% | — |
| UNH FY25 | $447.6B | +11.8% | — | 4.2% | 2.7% | 3.6% |
| CVS FY25 | $402.1B | +7.8% | — | 1.2% | 0.4% | 1.9% |
| CI FY25 | $274.9B | +11.2% | — | 3.3% | — | — |
| ELV FY25 | $199.1B | +12.5% | — | 3.6% | 2.8% | 1.6% |
| JNJ FY25 | $94.2B | +6.0% | 67.9% | — | 28.5% | 20.9% |
| MRK FY25 | $65.0B | +1.3% | — | — | 28.1% | 19.0% |
| ABBV FY25 | $61.2B | +8.6% | — | 24.6% | 6.9% | 29.1% |
| BMY FY25 | $48.2B | -0.2% | — | — | 14.6% | 26.7% |
| TMO FY25 | $44.6B | +3.9% | — | 17.4% | 15.0% | 14.1% |
| ABT FY25 | $44.3B | +5.7% | — | 18.2% | 14.7% | 16.7% |
Source: SEC EDGAR XBRL company facts (10-Q / 10-K), snapshot generated 2026-11-03 for 218 tickers. Q4 values are derived as the 10-K annual less the first nine months, since Q4 is not separately tagged in company facts; cash-flow quarterly values are derived from year-to-date filings the same way. Free cash flow = operating cash flow − capital expenditures. Blank cells mean the filing does not report that line item under a standard US-GAAP tag — nothing is estimated or filled in. Descriptive research, not investment advice. How EarnIQ builds fundamentals.